Methodological Flaws Raised in HERV-K102 Research, Previously Considered a Target for Acute Myeloid Leukemia
Background
Human endogenous retroviruses (HERVs) are genetic remnants inserted into the human genome millions of years ago, remaining mostly silent. Recently, cancer researchers noted that specific HERV expression is involved in cancer cell survival and immune evasion. The Zong research team reported that CRISPR-Cas9 deletion of the HERV-K102 envelope protein (K-Env) in acute myeloid leukemia (AML) cells induces apoptosis and pyroptosis via S100A9 protein and NLRP3 inflammasome activation. Ancient viral genes, previously considered non-coding or inactive remnants, have emerged as a new breakthrough in targeted therapy for leukemia.
In the search for new drug candidates, the process of proving the causality of target proteins must be rigorous. Failure to distinguish whether observed cell death is a direct immune response to specific gene deletion or non-specific necrosis due to gene-editing off-target effects or culture environment stress can lead to massive losses in subsequent development. Academic researchers have identified critical blind spots in the original paper's experimental design regarding cell death mechanisms, gene detection, and the validity of animal models, raising formal objections.
Key Findings
The rebuttal team systematically critiqued the four core methodologies supporting the original conclusion.
First, there was an absence of pathway-specific inhibitor experiments to distinguish pyroptosis from secondary necrosis. To prove pyroptosis, which involves cell membrane rupture, one must show that death is actually blocked by treating with caspase-1 or gasdermin D (GSDMD) specific inhibitors. Interpreting pyroptosis based solely on membrane damage markers without an inhibitor-treated group makes it difficult to rule out the risk of misidentifying secondary necrosis.
Second, there was a lack of rescue experiments to prove that the increase in S100A9 expression is the fundamental driver of cell death. If the phenotype observed after K-Env deletion is mediated by the S100A9 axis, then removing K-Env in an S100A9-deficient background should inhibit cell death; conversely, overexpression of S100A9 alone should recapitulate the same cell death. The critique points out that a molecular axis was established through simple correlation without such cross-verification.
Third, there is a problem with the non-specificity of PCR primers used for transcriptome analysis. The HERV family includes numerous homologs throughout the human genome. It was confirmed that the primers designed to amplify K-Env mRNA might have amplified other HERV-K subtypes or non-specific transcripts, undermining the reliability of the measured expression change values.
Fourth, there is a limitation to the immunocompromised xenograft mouse model used for in vivo verification. To prove the hypothesis that K-Env induces immune evasion, the interaction with the tumor microenvironment must be evaluated in a biological environment with a normal immune system. In immune-deficient animal models, the intrinsic immune-regulatory function of K-Env cannot be fully recapitulated, limiting the interpretation of the therapeutic efficacy reported in the original study.
Implications and Outlook
This rebuttal demands stricter experimental standards for next-generation anticancer research targeting ancient retroviral genes. When dealing with targets such as the HERV family, which feature repetitive similar sequences in the genome, specificity in transcriptome quantification must be ensured using ultra-high-precision long-read sequencing or unique-sequence-based digital PCR. When identifying cell death mechanisms, rather than relying on morphological changes or simple staining, it is necessary to establish a basic verification package including specific inhibitors and genetic rescue experiments.
The clinical translation of HERV-K102 as a prognostic marker or therapeutic agent should be approached with cautious re-evaluation rather than accepting the original claims at face value. The prerequisite for future research is to clearly determine whether the anticancer effect from gene deletion stems from target-specific inflammasome activation or is a phenomenon caused by off-target responses or complex stress responses.
Zong et al. reported that CRISPR-Cas9-mediated deletion of the HERV-K102 envelope (K-Env) induces apoptosis and pyroptosis in acute myeloid leukemia cells via S100A9/NLRP3 inflammasome activation. We examine four methodological concerns: the absence of evidence using a pathway-specific inhibitor to distinguish pyroptosis from secondary necrosis; the lack of a mechanistic rescue experiment confirming S100A9 as the proximal driver; the non-specificity of primers at the mRNA level; and the inability of the immunocompromised xenograft model to capture immune evasion by K-Env. The prognostic and therapeutic implications of the study require qualification.
This rebuttal provides important quality control guidelines for biotechs and drug development teams developing HERV-targeted immunotherapies. To target retroviral sequences dispersed in the human genome, designing unique primers to filter out false-positive signals during the transcriptome quantification stage is essential. If a pipeline is based on a pyroptosis-inducing mechanism, it must include GSDMD inhibitor and S100A9 genomic editing rescue experiments in the Go/No-Go criteria for early candidate efficacy evaluation to reduce subsequent clinical failure costs. Furthermore, when evaluating immune activation mechanisms, the preemptive use of humanized mice or syngeneic tumor models is necessary to accurately determine target efficacy.